SPOTLIGHT: CuraGen sells Belinostat stake to TopoTarget

CuraGen Corporation has sold its stake in Belinostat to TopoTarget for $39 million upfront in a combination of cash and stock. TopoTarget will now take full control of the cancer drug's development. "CuraGen has been a good partner and helped us over a high risk period," said Dr. Peter Buhl Jensen, CEO of TopoTarget. CuraGen said the move allows it to focus on other clinical programs. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.